Drugs / 11C-DASB
11C-DASB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03970239 | May 2019 → Feb 2022 | Parkinson disease, impulse control disorder | Hospices Civils de Lyon | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03581305 Comparator | Nov 2018 → Apr 2022 | AIDS dementia complex, HIV infectious disease, depressive disorder | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C]-DASB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03970239 ↗ |
| Known as | [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile | “Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)” NCT03970239 ↗ |
| Modality | Diagnostic / imaging agent | “High resolution positron emission tomography (PET) of the brain and radioligands targeted against the serotonergic (11C-DASB) system.” NCT03581305 ↗ |
| Route | Intravenous | “single intravenous administration of approximately 4 Megabecquerel/kilogram (MBq/kg)” NCT03970239 ↗ |